ALK and non-small cell lung carcinoma: Furthermore, ALK-rearranged NSCLC pts exhibiting a history of prior ALKi treatment are reported to harbor a high incidence of CNS metastases, i.e., from approximately 45 to 70 %, which suggests that BM is the most common pattern of failure of ALKi [8, 9, 17–21].